- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Alembic Pharma secures USFDA tentative approval for Larotrectinib Capsules (25 mg, 100 mg). This product targets a US$ 9.1 Cr market. As sole first applicant, Alembic may gain 180-day generic exclusivity upon final approval.